Author

P. Conley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1 Assay:DNA methylation· 1

Frequent Co-Authors

G. Wu· 2 shared A. Agarwal· 1 shared A. H. Skalet· 1 shared A. N. Anderson· 1 shared B. Davis· 1 shared C. D. Klocke· 1 shared C. Eden· 1 shared D. Goldman· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Wu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Analysis of uveal melanoma scRNA sequencing data identifies neoplastic-immune hybrid cells that exhibit metastatic potential

A. N. Anderson, P. Conley, C. D. Klocke, S. K. Sengupta, T. L. Robinson, Y. Fan, J. A. Jones, S. L. Gibbs, A. H. Skalet, G. Wu, M. H. Wong

The paper identifies neoplastic-immune hybrid cells in uveal melanoma scRNA-seq data that exhibit metastatic potential through gene expression and ligand-receptor analysis.

bioRxiv · Oct 24, 2023 · PreprintCancer Biology

The transcriptional and epigenetic reprogramming associated with chronic IL1β-mediated expansion and myeloid priming in TET2 deficient stem and progenitor cells.

J. McClatchy, R. Strogantsev, E. Wolfe, H.-Y. Lin, M. Mohammadhosseini, B. Davis, C. Eden, D. Goldman, W. Fleming, P. Conley, G. Wu, L. Cimmino, H. Mohammed, A. Agarwal

This study shows IL1β promotes myeloid expansion and self-renewal in TET2-deficient hematopoietic stem/progenitor cells, leading to a premalignant phenotype that can be suppressed by IL1R1 inhibition.

bioRxiv · Sep 15, 2022 · PreprintCancer Biology